Gilead Sciences, Inc. $GILD Shares Purchased by Global X Japan Co. Ltd.

Key Points

• Global X Japan boosted its stake in Gilead by 334.6% in Q4, buying 37,591 shares to hold 48,825 shares worth about $5.99 million.
• Gilead beat Q results (EPS $1.86 vs $1.83; revenue $7.93B vs $7.68B) and set FY 2026 guidance of 8.45–8.85 EPS, prompting several analyst price-target raises and a consensus "Moderate Buy" (avg. PT $157.62).
• The company raised its quarterly dividend to $0.82 ($3.28 annualized, ~2.4% yield; ex-dividend March 13), while insiders have sold roughly 309,280 shares (~$44.07M) in the past 90 days.

Global X Japan Co. Ltd. boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 334.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,825 shares of the biopharmaceutical company's stock after buying an additional 37,591 shares during the period. Global X Japan Co. Ltd.'s holdings in Gilead Sciences were worth $5,993,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of GILD. Corundum Trust Company INC purchased a new stake in Gilead Sciences during the 3rd quarter valued at about $26,000. Howard Hughes Medical Institute purchased a new position in Gilead Sciences in the 2nd quarter worth approximately $30,000. MTM Investment Management LLC boosted its holdings in shares of Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 176 shares during the last quarter. Kilter Group LLC acquired a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $33,000. Finally, Board of the Pension Protection Fund purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $37,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $136.88 on Friday. The business's fifty day simple moving average is $143.90 and its 200-day simple moving average is $128.44. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The firm has a market cap of $169.90 billion, a PE ratio of 20.22, a price-to-earnings-growth ratio of 1.81 and a beta of 0.37. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. Gilead Sciences's revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the firm posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be paid a dividend of $0.82 per share. The ex-dividend date is Friday, March 13th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. Gilead Sciences's payout ratio is presently 48.45%.

Insiders Place Their Bets

In related news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the sale, the director directly owned 8,920 shares in the company, valued at $1,101,620. This trade represents a 35.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $144.23, for a total value of $432,690.00. Following the sale, the chief financial officer owned 179,191 shares in the company, valued at $25,844,717.93. This trade represents a 1.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 309,280 shares of company stock worth $44,068,850. 0.27% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $150.00 to $160.00 and gave the company an "overweight" rating in a report on Wednesday, February 11th. Argus boosted their price objective on Gilead Sciences from $135.00 to $165.00 and gave the stock a "buy" rating in a research note on Thursday, February 19th. Royal Bank Of Canada upped their target price on Gilead Sciences from $103.00 to $118.00 and gave the company a "sector perform" rating in a report on Wednesday, February 11th. Rothschild & Co Redburn lifted their price target on Gilead Sciences from $159.00 to $170.00 and gave the stock a "buy" rating in a report on Tuesday, February 17th. Finally, Barclays began coverage on shares of Gilead Sciences in a research report on Friday, February 20th. They set an "equal weight" rating and a $155.00 price target on the stock. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $157.62.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.